Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.43 |
| ▸ | NAMPT | P43490 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3257474 | 0.85 | OPRD1 (0.52) | OPRD1OPRK1GPR119NAMPTPOLB | |
| SCHEMBL15941976 | 0.84 | OPRD1 (0.38) | OPRD1OPRK1 | |
| SCHEMBL16992549 | 0.79 | OPRD1 (0.48) | OPRD1OPRK1GPR119NAMPTFAAH | |
| 1-Methylimidazole SCHEMBL6236830 | 0.77 | OPRD1 (0.46) | OPRD1OPRK1GPR119NAMPTPOLB | |
| SCHEMBL5472913 | 0.77 | GPR119 (0.52) | OPRD1OPRK1GPR119POLB | |
| SCHEMBL4979176 | 0.76 | OPRD1 (0.46) | OPRD1OPRK1GPR119NAMPTPOLB | |
| SCHEMBL26931893 | 0.75 | PDE4A (0.45) | OPRD1OPRK1GPR119POLBPDE4A | |
| SCHEMBL12193713 | 0.74 | POLB (0.46) | OPRD1OPRK1GPR119POLB | |
| SCHEMBL1513657 | 0.74 | TSHR (0.55) | OPRD1OPRK1GPR119 | |
| SCHEMBL24159231 | 0.73 | OPRD1 (0.34) | OPRD1OPRK1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714446-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-03-25 | — | — | EP | disclosed |
| EP-4413985-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2024-08-14 | — | — | EP | disclosed |
| CN-109851610-B | Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists | 赫普泰雅治疗有限公司 | 2021-09-21 | — | — | CN | disclosed |
| US-10961225-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20200325118-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2020-10-15 | — | — | US | disclosed |
| US-10689368-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-23 | — | — | US | disclosed |
| US-20190337925-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2019-11-07 | — | — | US | disclosed |
| US-10385039-B2 | Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-08-20 | — | — | US | disclosed |
| US-20190112294-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARNIC M1 RECEPTOR AND/OR M4 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2019-04-18 | — | — | US | disclosed |
| US-10196380-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-02-05 | — | — | US | disclosed |
| US-20170015650-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| US-20150376179-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2015-12-31 | — | — | US | disclosed |
| EP-2953940-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2015-12-16 | — | — | EP | disclosed |
| WO-2014122474-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | WO | disclosed |
| US-8603975-B2 | Cyclic peptide compounds | ASTELLAS PHARMA INC. (JP) | 2013-12-10 | — | — | US | disclosed |
| EP-2150269-B1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2012-11-21 | — | — | EP | disclosed |
| EP-2455098-A1 | New cyclic peptide compounds | Astellas Pharma Inc. (JP) | 2012-05-23 | — | — | EP | disclosed |
| US-20100120672-A1 | CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2150269-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | Astellas Pharma Inc. (JP) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008139986-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC., (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325118-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | CHRM1, CHRM2, CHRM4 | OPRD1 363/4885OPRK1 417/4885GPR119 74/4885 |
| US-20100120672-A1 | CYCLIC PEPTIDE COMPOUNDS | VIP, HAVCR2, ZC3HAV1 | OPRD1 3487/4885OPRK1 2721/4885GPR119 1509/4885 |
| US-20170015650-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | OPRD1 350/4885OPRK1 387/4885GPR119 69/4885 |
| US-10196380-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | OPRD1 376/4885OPRK1 397/4885GPR119 71/4885 |
| US-20190112294-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARNIC M1 RECEPTOR AND/OR M4 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | OPRD1 189/4885OPRK1 237/4885GPR119 60/4885 |
| US-10961225-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor | CHRM1, CHRM2, CHRM4 | OPRD1 363/4885OPRK1 417/4885GPR119 74/4885 |
| US-20150376179-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | OPRD1 26/4885OPRK1 25/4885GPR119 89/4885 |
| US-10689368-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor | CHRM1, CHRM2, CHRM4 | OPRD1 363/4885OPRK1 417/4885GPR119 74/4885 |
| US-10385039-B2 | Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists | CHRM1, CHRM2, CHRM5 | OPRD1 189/4885OPRK1 237/4885GPR119 60/4885 |
| US-20190337925-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | CHRM1, CHRM2, CHRM4 | OPRD1 363/4885OPRK1 417/4885GPR119 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.